Inclusion Criteria:

          -  Lead In and Cohort 1

               1. Previously treated AML based on the revised 2017 European LeukemiaNet (ELN)
                  criteria and having ≥10% blasts in bone marrow or peripheral blood

               2. Age ≥18 years

          -  Cohort 2

               1. Untreated AML per ELN criteria with high risk features

               2. Age ≥ 65 years and ineligible for intensive chemotherapy because of older than 75
                  years, cardiac disease or prior anthracycline use or high probability of
                  treatment-related mortality

          -  Life expectancy reasonably adequate for evaluating the treatment

          -  White blood cell (WBC) count of 10 × 109/L or less. (Use of hydroxyurea to control WBC
             is allowed till 48 hours prior to protocol treatment)

          -  Adequate renal function: Creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine
             clearance > 40 mL/minute (measured or calculated according to the Cockcroft-Gault
             formula)

          -  Adequate liver function

               -  Total bilirubin ≤ 1.5 x ULN

               -  ALT and AST both ≤ 2.5 x institutional ULN or ≤ 5 times the ULN for patients with
                  leukemic involvement of liver

        Exclusion Criteria:

          -  Prior treatment for antecedent hematological disorders with hypomethylating agent
             (more than 2 cycles, those with exposure to <2 cycles will be allowed), venetoclax, or
             chemotherapy for antecedent hematologic disorders (treatment with other agents
             including hydroxyurea for myelodysplastic syndrome or myeloproliferative neoplasm is
             permitted)

          -  Favorable risk AML per ELN 2017 criteria

          -  Known active CNS involvement by leukemia